Drugs  ||| S:0 E:6 ||| NNS
and  ||| S:6 E:10 ||| CC
toxins-associated  ||| S:10 E:28 ||| JJ
pulmonary  ||| S:28 E:38 ||| JJ
arterial  ||| S:38 E:47 ||| JJ
hypertension ||| S:47 E:59 ||| NN
:  ||| S:59 E:61 ||| :
lessons  ||| S:61 E:69 ||| NNS
learned  ||| S:69 E:77 ||| VBN
and  ||| S:77 E:81 ||| CC
challenges  ||| S:81 E:92 ||| NNS
ahead  ||| S:92 E:98 ||| RB
Since  ||| S:98 E:104 ||| IN
the  ||| S:104 E:108 ||| DT
identification  ||| S:108 E:123 ||| NN
of  ||| S:123 E:126 ||| IN
the  ||| S:126 E:130 ||| DT
link  ||| S:130 E:135 ||| NN
between  ||| S:135 E:143 ||| IN
pulmonary  ||| S:143 E:153 ||| FW
arterial  ||| S:153 E:162 ||| FW
hypertension  ||| S:162 E:175 ||| FW
( ||| S:175 E:176 ||| -LRB-
PAH ||| S:176 E:179 ||| NNP
)  ||| S:179 E:181 ||| -RRB-
and  ||| S:181 E:185 ||| CC
exposure  ||| S:185 E:194 ||| NN
to  ||| S:194 E:197 ||| TO
certain  ||| S:197 E:205 ||| JJ
drugs  ||| S:205 E:211 ||| NNS
and  ||| S:211 E:215 ||| CC
toxins  ||| S:215 E:222 ||| VBP
nearly  ||| S:222 E:229 ||| RB
fifty  ||| S:229 E:235 ||| JJ
years  ||| S:235 E:241 ||| NNS
ago ||| S:241 E:244 ||| RB
,  ||| S:244 E:246 ||| ,
the  ||| S:246 E:250 ||| DT
expanding  ||| S:250 E:260 ||| VBG
landscape  ||| S:260 E:270 ||| NN
of  ||| S:270 E:273 ||| IN
available  ||| S:273 E:283 ||| JJ
pharmaceuticals  ||| S:283 E:299 ||| NNS
and  ||| S:299 E:303 ||| CC
illicit  ||| S:303 E:311 ||| JJ
drugs  ||| S:311 E:317 ||| NNS
is  ||| S:317 E:320 ||| VBZ
further  ||| S:320 E:328 ||| RB
fueling  ||| S:328 E:336 ||| VBG
this  ||| S:336 E:341 ||| DT
association ||| S:341 E:352 ||| NN
.  ||| S:352 E:354 ||| .
While  ||| S:354 E:360 ||| IN
some  ||| S:360 E:365 ||| DT
causative  ||| S:365 E:375 ||| JJ
agents  ||| S:375 E:382 ||| NNS
in  ||| S:382 E:385 ||| IN
drugs  ||| S:385 E:391 ||| NNS
and  ||| S:391 E:395 ||| CC
toxins  ||| S:395 E:402 ||| VB
associated  ||| S:402 E:413 ||| VBN
PAH  ||| S:413 E:417 ||| NNP
( ||| S:417 E:418 ||| -LRB-
D ||| S:418 E:419 ||| NNP
& ||| S:419 E:420 ||| CC
T-APAH ||| S:420 E:426 ||| NNP
)  ||| S:426 E:428 ||| -RRB-
have  ||| S:428 E:433 ||| VBP
been  ||| S:433 E:438 ||| VBN
identified ||| S:438 E:448 ||| VBN
,  ||| S:448 E:450 ||| ,
little  ||| S:450 E:457 ||| RB
is  ||| S:457 E:460 ||| VBZ
known  ||| S:460 E:466 ||| VBN
about  ||| S:466 E:472 ||| IN
the  ||| S:472 E:476 ||| DT
exact  ||| S:476 E:482 ||| JJ
biology  ||| S:482 E:490 ||| NN
and  ||| S:490 E:494 ||| CC
clinical  ||| S:494 E:503 ||| JJ
implications  ||| S:503 E:516 ||| NNS
of  ||| S:516 E:519 ||| IN
the  ||| S:519 E:523 ||| DT
disease ||| S:523 E:530 ||| NN
.  ||| S:530 E:532 ||| .
In  ||| S:532 E:535 ||| IN
this  ||| S:535 E:540 ||| DT
review ||| S:540 E:546 ||| NN
,  ||| S:546 E:548 ||| ,
we  ||| S:548 E:551 ||| PRP
discuss  ||| S:551 E:559 ||| VB
the  ||| S:559 E:563 ||| DT
historical  ||| S:563 E:574 ||| JJ
evidence  ||| S:574 E:583 ||| NN
that  ||| S:583 E:588 ||| WDT
links  ||| S:588 E:594 ||| VBZ
PAH  ||| S:594 E:598 ||| NNP
with  ||| S:598 E:603 ||| IN
exposure  ||| S:603 E:612 ||| NN
to  ||| S:612 E:615 ||| TO
anorexinogens ||| S:615 E:628 ||| VB
,  ||| S:628 E:630 ||| ,
cocaine ||| S:630 E:637 ||| NN
,  ||| S:637 E:639 ||| ,
and  ||| S:639 E:643 ||| CC
methamphetamines  ||| S:643 E:660 ||| NNS
and  ||| S:660 E:664 ||| CC
concentrate  ||| S:664 E:676 ||| VB
on  ||| S:676 E:679 ||| IN
what  ||| S:679 E:684 ||| WP
is  ||| S:684 E:687 ||| VBZ
known  ||| S:687 E:693 ||| VBN
about  ||| S:693 E:699 ||| IN
potential  ||| S:699 E:709 ||| JJ
pathogenesis ||| S:709 E:721 ||| NN
,  ||| S:721 E:723 ||| ,
clinical  ||| S:723 E:732 ||| JJ
manifestations ||| S:732 E:746 ||| NNS
,  ||| S:746 E:748 ||| ,
and  ||| S:748 E:752 ||| CC
current  ||| S:752 E:760 ||| JJ
management ||| S:760 E:770 ||| NN
.  ||| S:770 E:772 ||| .
We  ||| S:772 E:775 ||| PRP
conclude  ||| S:775 E:784 ||| VBP
that  ||| S:784 E:789 ||| IN
future  ||| S:789 E:796 ||| JJ
research  ||| S:796 E:805 ||| NN
should  ||| S:805 E:812 ||| MD
focus  ||| S:812 E:818 ||| VB
on  ||| S:818 E:821 ||| IN
studies  ||| S:821 E:829 ||| NNS
looking  ||| S:829 E:837 ||| VBG
at  ||| S:837 E:840 ||| IN
clinical  ||| S:840 E:849 ||| JJ
outcome  ||| S:849 E:857 ||| NN
and  ||| S:857 E:861 ||| CC
susceptibility  ||| S:861 E:876 ||| JJ
factors ||| S:876 E:883 ||| NNS
.  ||| S:883 E:885 ||| .
